Source: CureToday articles
INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.
Recent Content
- Molecular profiling and risk stratification in solitary bone plasmacytoma
- Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials
- Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
- Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
- Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
- Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
- Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
- Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
- Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab